eCommons@AKU

Section of Internal Medicine

eCommons@AKU
Department of Medicine

8-17-2021

Discrepancy between PCR based SARS-CoV-2 tests suggests the
need to re-evaluate diagnostic assays
Zain Mushtaq
Sadia Shakoor
Akber Kanji
Najma Shaheen
Asghar Nasir

See next page for additional authors

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_med_intern_med
Digital
Part of the Internal Medicine Commons, Life Sciences Commons, Pathology Commons, and the Virus
Commons
Diseases Commons
Network
Logo

Authors
Zain Mushtaq, Sadia Shakoor, Akber Kanji, Najma Shaheen, Asghar Nasir, Zeeshan Ansar Ahmed, Imran
Ahmed, Syed Faisal Mahmood, Rumina Hasan, and Zahra Hasan

(2021) 14:316
Mushtaq et al. BMC Res Notes
https://doi.org/10.1186/s13104-021-05722-5

BMC Research Notes
Open Access

RESEARCH NOTE

Discrepancy between PCR based
SARS‑CoV‑2 tests suggests the need
to re‑evaluate diagnostic assays
Muhammad Zain Mushtaq1, Sadia Shakoor2,3, Akbar Kanji2, Najma Shaheen2, Asghar Nasir2, Zeeshan Ansar2,
Imran Ahmed2, Syed Faisal Mahmood1, Rumina Hasan2 and Zahra Hasan2*

Abstract
Objective: We investigated the discrepancy between clinical and PCR-based diagnosis of COVID-19. We compared
results of ten patients with mild to severe COVID-19. Respiratory samples from all cases were tested on the Roche
SARS-CoV-2 (Cobas) assay, Filmarray RP2.1 (bioMereiux) and TaqPath™ COVID19 (Thermofisher) PCR assays.
Results: Laboratory records of ten patients with mild to severe COVID-19 were examined. Initially, respiratory
samples from the patients were tested as negative on the SARS-CoV-2 R
 oche® assay. Further investigation using the
®
BIOFIRE Filmarray RP2.1 assay identified SARS-CoV-2 as the pathogen in all ten cases. To investigate possible discrepancies between PCR assays, additional testing was conducted using the TaqPath™ COVID19 PCR. Eight of ten samples
were positive for SARS-CoV-2 on the TaqPath assay. Further, Spike gene target failures (SGTF) were identified in three
of these eight cases. Discrepancy between the three PCR assays could be due to variation in PCR efficiencies of the
amplification reactions or, variation at primer binding sites. Strains with SGTF indicate the presence of new SARSCoV-2 variant strains. Regular modification of gene targets in diagnostic assays may be necessary to maintain robustness and accuracy of SARS-CoV-2 diagnostic assays to avoid reduced case detection, under-surveillance, and missed
opportunities for control.
Keywords: SARS-CoV-2, PCR, COVID-19, Spike gene
Introduction
Robust diagnostic testing for SARS-CoV-2 is integral to
disease surveillance and control of COVID-19. Reversetranscription polymerase chain reaction (RT-PCR) based
assays are the most widely used assay to detect RNA
viruses. Selection of target genes for diagnostic assays is
critical and most diagnostic assays in use include two or
more gene targets to maximize diagnostic accuracy (sensitivity and specificity) [1].
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SARS-CoV-2 was identified in December 2019 as
a beta-coronavirus of the Sarbecovirus family, with a
positive-sense RNA genome of 29.9 kb in size, fourteen
open reading frames (orf) encoding accessory nonstructural viral proteins, the nucleocapsid (N), membrane
(M), spike (S), and envelope (E) structural proteins [2]. In
order for SARS-CoV-2 testing to be reliable, it is necessary that assays that identify viral RNA should be consistent and comparable. When recommendations for
SARS-CoV-2 diagnostics were first made, the E gene
and RdRp were amongst recommended potential target
geness [3]. The E gene is known to have higher sensitivity
while the inclusion of the N, S, and RNA dependent RNA
polymerase (RdRp) genes are recommended for higher
specificity [4].
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No test is 100% accurate and false-negative results with
commercially available diagnostic assays have been documented since the early days of the pandemic [5]. Falsenegative results in the context of symptomatic COVID-19
illness may have several determinants, such as the clinical specimen type (sputum and bronchoalveolar lavage
have higher detection rates than nasal and naso- or oropharyngeal specimens) [2], temporal variation in viral
shedding [6], as well as diagnostic primer/probe mismatches with infecting SARS-CoV2 virus sequence [7].
However, in the context of increasing reports of SARSCoV-2 variants seeing false negative results in diagnostic
tests are of particular concern, as there is a wider implication on misidentification of asymptomatic cases as
well, particularly [8, 9].

Main text
Methods

Patient specimens were collected from cases admitted
into the COVID-19 unit at The Aga Khan University
Hospital, Karachi, Pakistan. Inclusion criteria cases were
those who had a high clinical suspicion for COVID-19
but had a negative SARS-CoV-2 PCR test conducted at
the time of their hospital admission using the SARSCoV-2 Cobas® 6800 assay (Roche diagnostics Rotkreuz,
Switzerland). The following were considered as signs
of COVID-19: classical presentation in terms of signs
and symptoms, need for supplemental oxygen support,
deranged inflammatory parameters and absence of alternative diagnosis. Exclusion criteria were cases with the
abovementioned clinical signs who had an alternative
cause for their respiratory illness and those who had a
positive SARS-CoV-2 PCR results.
Patients were diagnosed with COVID-19 based on clinical, laboratory and radiological parameters which were
used to assess the severity of disease. Clinical parameters included physical signs like tachypnea, tachycardia, hypoxia (SpO2 < 94% at room air), while laboratory
investigations included hypoxemia (PaO2 < 80 mm Hg),
hyperferritinemia, raised LDH and CRP. Radiologically,
patients were assessed on the basis of Computerised
tomography (CT) scan or X-ray chest.
COVID-19 severity was assessed on the basis of need
for supplemental oxygen support, raised levels of inflammatory markers and more than 50% involvement of lungs
on a CT scan or X- ray chest. Severity was ranked as per
the WHO ordinal scale [10]. In each case, nasopharyngeal swab specimens were first tested for SARS-CoV-2
RNA using the SARS-CoV-2 C
 obas® (Roche diagnostics Rotkreuz, Switzerland) targeting orf1-ab and E
genes. In the case that the SARS-CoV-2 Roche RT-PCR
was found to be negative, a second PCR was conducted
using the BIOFIRE® Filmarray RP2.1 test (bioMereiux,
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Marcy-l’Étoile, France) which includes four bacterial and
18 viral pathogen targets i.e. Adenovirus, influenza A
viruses H1, 2009H1, H3 (FluA-H1, FluA-2009H1, FluAH3), influenza B virus (FluB), parainfluenza virus types
1–4 (Para 1–4), coronaviruses 229E, HKU1, OC43, and
NL63 (CoV-HKU1, NL63, 229E, OC43), MERS-CoV
(MERS coronavirus), human metapneumovirus (hMPV),
Respiratory Syncytial Virus (RSV), human rhinovirus/
enterovirus (Rhino/Entero), Chlamydia pneumoniae,
Mycoplasma pneumoniae, Bordetella pertussis, and Bordetella parapertussis in addition to SARS-CoV2 (S and
M gene gene targets). All the RT-PCR assays were conducted at the Aga Khan University, Karachi. SARS-CoV-2
Cobas® and BIOFIRE® Filmarray RP2.1 tests were conducted at the AKUH Clinical Laboratories which are
accredited by the College of American Pathologists. For
further investigation of discrepancies, a third PCR was
conducted using the TaqPath™ COVID19 (Thermo,
Applied Biosystems, USA) assay (S, N and orf1ab gene
targets) at the AKU Research Laboratory. Assay details
are provided in Additional file 1.
Results

We report on ten patients with COVID-19 from Karachi,
Pakistan from 18th January to 18th February 2021, presenting to acute care at a tertiary hospital. The patients
were investigated for COVID-19 based on their clinical
presentation. They were mostly aged 65–74 years (60%),
followed by two cases aged > 75 years and two below
54 years of age, Table 1. Patients had between five and
forty days of illness with a median period of 8 days. Laboratory parameters found to be raised in all cases were:
hyperferritinemia, high biomarker levels (C-reactive protein, D-dimer), details not shown. Chest imaging showed
ground-glass opacities or bilateral parenchymal infiltrates, and high population prevalence in all cases. Respiratory samples tested by PCR for SARS-CoV-2 using
the SARS-CoV-2 Cobas Roche assay were negative in
all cases. Due to a high clinical suspicion for COVID19, samples were further set for testing on the Filmarray
RP2.1 platform. In all ten cases, Filmarray results indicated SARS-CoV-2 RNA to be present in the respiratory
samples.
To further investigate this, the same ten respiratory
specimens tested by Filmarray test were subsequent tested
for the presence of SARS-CoV-2 RNA on the TaqPath™
COVID19 assay. Here we found, eight respiratory specimens to be positive and two were negative (Table 1). All
three gene targets in the TaqPath assay (Orf1ab, N and
S) were detected in six samples. In one sample N and S
were detected but Orf1ab target amplification was absent.
S gene target failure (SGTF) was identified in three specimens. The CT values of gene targets amplified in the
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Table 1 Description of COVID-19 patients and their differential diagnostic PCR results
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TaqPath assay were CT 31 and below indicating, high to
medium viral loads of SARS-CoV-2 [11].
Discussion

Our data suggest show variations between diagnostic
platforms for SARS-CoV-2. A summary of differential
commercial RT-PCR test results and possible explanations are given in Table 1. Single nucleotide mismatch
in primer/ probe, especially in the 3′ binding region,
may result in failure of target binding and false-negative
results [6]. The orf1ab, N, and S regions are shown to be
the most mutable in SARS-CoV-2, whilst E gene and M
gene have been reported to be relatively less error prone
[7]. Genomic sequencing would be necessary to further
delineate the assumed polymorphisms in SARS-CoV-2
orf1ab, N, E, and S genes that could result in the discrepancies identified. However, as sequences of target regions
in commercial assays are proprietary, a direct comparison between the binding regions of orf1ab in the Roche
and TaqPath assays; and of the S region in the Filmarray
and TaqPath assays cannot be made.
The TaqPath COVID19 assay has been used to screen
for UK Variant of Concern (B.1.1.7) with SGTF used as
a surrogate marker for H69-V70 variant detection [8].
We have limited data on genomic surveillance of SARSCoV-2 in Pakistan however, we have recently identified
the introduction of B.1.1.7 lineage strains (unpublished
data, sequence submitted). The variability observed in the
three cases with S gene drop-out suggests the presence
of new variants. Importantly, given the CT values of the
gene targets detected in each case by the TaqPath assay,
the samples had a medium to high viral load. Therefore,
it is unlikely that discrepancy between SARS-CoV-2 diagnosis between assays was due to variation between assay
sensitivity, further supporting our hypothesis.
These cases we present illustrate the importance of
taking into account both the quality of the diagnostic
assay and its appropriate design strategy to best capture
SARS-CoV-2 strains moving forward. This report is a
problem statement and has not made any comparisons
or tested any hypotheses. We suggest that the issue of
diagnostic test discrepancy be further studied through
systematic research. While keeping primer and probe
information proprietary is the norm, the medical and
research community will benefit from requests from
scientists to reveal further information, which is often
not made available even upon request [12]. We propose frequent evaluation of national databases of viral
genome sequences to inform standards on diagnostic
assays. Such an initiative can advise on targets with
low mutation frequency, such that > 99% of circulating variants are detectable using selected primers and
probes. Further, in keeping with the rapidly evolving
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nature of the SARS-CoV-2 genome it is of particular
consequence that there be a regular review of the target
primers being used and an improvement of diagnostic
assays to keep up the expected sensitivity and specificity required of diagnostic assays for COVID-19.

Limitations
Our results are subject to inherent limitation due to
small sample size of the study. Further, as we do not have
genome sequences available of the SARS-CoV-2 strains
described in the study, we cannot ascertain the polymorphisms present in the genomes. Further, due to the proprietary nature of the commercial assays used it would
not be possible to associate sequence variations with differential amplification frequencies of the PCR tests.
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